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The E3 SUMO ligase PIASγ is a 
novel interaction partner regulating 
the activity of diabetes associated 
hepatocyte nuclear factor-1α
Alba Kaci1,2,3, Magdalena Keindl1, Marie H. Solheim1, Pål R. Njølstad1,3, Lise Bjørkhaug4 & 
Ingvild Aukrust  1,2
The transcription factor hepatocyte nuclear factor-1α (HNF-1A) is involved in normal pancreas 
development and function. Rare variants in the HNF1A gene can cause monogenic diabetes, while 
common variants confer type 2 diabetes risk. The precise mechanisms for regulation of HNF-1A, 
including the role and function of post-translational modifications, are still largely unknown. Here, 
we present the first evidence for HNF-1A being a substrate of SUMOylation in cellulo and identify 
two lysine (K) residues (K205 and K273) as SUMOylation sites. Overexpression of protein inhibitor 
of activated STAT (PIASγ) represses the transcriptional activity of HNF-1A and is dependent on 
simultaneous HNF-1A SUMOylation at K205 and K273. Moreover, PIASγ is a novel HNF-1A interaction 
partner whose expression leads to translocation of HNF-1A to the nuclear periphery. Thus, our findings 
support that the E3 SUMO ligase PIASγ regulates HNF-1A SUMOylation with functional implications, 
representing new targets for drug development and precision medicine in diabetes.
Hepatocyte nuclear factor-1α (HNF-1A) is a transcription factor encoded by the HNF1A gene, which regulates 
several pancreas and liver specific genes, and plays a role in pancreas/liver development and function1. In pan-
creatic β-cells, HNF-1A is part of a regulatory circuit involving other transcription factors like the pancreatic 
duodenal homeobox-1 (PDX-1), the hepatocyte nuclear factor-4 alpha (HNF-4A) and-1 beta (HNF-1B), which 
are important for normal glucose-induced insulin secretion1,2. In mice, loss of Hnf1a function results in multiple 
metabolic abnormalities including defects in pancreatic β-cell glucose sensing, hypercholesterolemia and aberrant 
expression of genes involved in pancreatic islet development and metabolism3, further illustrating the important 
role of HNF-1A in controlling pancreatic-islet β-cell function4. Although rare variants in HNF1A are primar-
ily associated with a monogenic form of diabetes known as Maturity-Onset Diabetes of the Young (MODY3; 
HNF1A-MODY, OMIM #600496)5, common HNF1A variants represent risk factors for type 2 diabetes6–8.
In its active form, HNF-1A functions as a homodimer or heterodimer (with HNF-1B), and both complexes 
are stabilized by the dimerization cofactor DCoH9. Other cofactors involved in HNF-1A transcriptional regula-
tion are the CREB-binding protein (CBP)10, the CBP-associated factor (P/CAF)10, and the high mobility group 
protein-B111, exerting a positive effect on HNF-1A transactivation function. Post-translational modifications 
(PTMs) are known to regulate HNF-1A. Phosphorylation of HNF-1A by the ATM kinase, results in enhanced 
HNF-1A transcriptional activity12, and ubiquitin-induced proteasomal degradation is a mechanism for its intra-
cellular clearance13. Still, the precise mechanisms for transcriptional regulation of HNF-1A, including the role and 
function related to PTMs, are so far largely unknown.
SUMOylation represents a highly dynamic and reversible ATP-consuming PTM process of proteins, involv-
ing a cascade of different proteins/enzymes including an E1 (activating enzyme), E2 (conjugating enzyme), an 
E3 SUMO ligase, and is reversed by the SUMO-specific proteases of the SENP family14. In pancreatic β-cells, 
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SUMOylation regulates the function of key proteins involved in insulin secretion, including transcriptions fac-
tors like MafA15 and PDX-116, the glucose sensor glucokinase17, and the voltage-dependent K(+) (Kv) channel 
Kv2.118. Thus, targeting the SUMOylation cascade has been proposed as a relevant diabetes treatment approach19.
Here, we report the first evidence that HNF-1A is modified by SUMO-3 in cellulo and that its level of 
SUMOylation is enhanced by the action of the E3 SUMO ligase; protein inhibitor of activated STAT (PIASγ). 
Although the presence of SUMO-3 and PIASγ did not affect the nuclear level of HNF-1A protein, or its DNA 
binding ability, PIASγ repressed the transcriptional activity of HNF-1A. Furthermore, PIASγ was demonstrated 
to interact with HNF-1A, and sequestrated HNF-1A in the nuclear periphery, hence inducing its transcriptional 
repression of the HNF-1A target genes Ace2 and Slc2a2. In this study, we report for the first time that both 
SUMOylation of HNF-1A by SUMO-3 and its interaction with PIASγ are novel mechanisms regulating the 
nuclear localization and hence transcriptional activity of HNF-1A.
Results
HNF-1A is a target for SUMO-3 modification. To investigate whether HNF-1A is a target of SUMOylation, 
we overexpressed HEK293 cells with HNF-1A (V5-tagged), SUMO-1 or SUMO-3 (HA-tagged), and in the pres-
ence or absence of the E2 enzyme Ubc9 (HA-tagged) or the E3 SUMO ligase, PIASγ (Flag-tagged). HNF-1A 
was further isolated by V5-tag immunoprecipitation and analyzed by SDS-PAGE and immunoblotting using 
tag-specific (HA and V5) antibodies (Fig. 1a). In the immunoprecipitated samples analyzed by anti-HA antibody, 
several higher molecular-mass bands ranging from ∼90–200 kDa, corresponding to HA-SUMO-conjugated 
HNF-1A was observed in cells co-transfected with SUMO-3 (Fig. 1a). Notably, HNF-1A seems to be preferen-
tially modified by SUMO-3, versus SUMO-1, as only one faint high molecular-mass band could be observed in 
Figure 1. HNF-1A is SUMOylated by SUMO-3 and PIASγ in HEK293 cells. (a) SUMOylation of HNF-1A 
analyzed in HEK293 cells transiently transfected with V5-tagged HNF-1A or empty vector together with HA-
tagged SUMO-1 or SUMO-3, HA-tagged UBC9 and/or Flag-tagged PIASγ. Cells were lysed in the presence 
of N-Ethylmaleimide and protease inhibitors, and subjected to immunoprecipitation using anti-V5 antibody. 
The precipitate (upper half) and 10 µg input (lower half) were separated by SDS-PAGE and immunoblotting 
using anti-HA, anti-V5 and anti-Flag antibodies. Full-length blots are presented in Supplementary Fig. S3. This 
experiment was replicated in three independent experimental days (n = 3). (b) De-SUMOylation of HNF-1A by 
SENP-1. HEK293 cells were transiently transfected with V5-tagged HNF1A or empty vector together with HA-
tagged SUMO3, Flag-tagged PIASγ, and increasing amounts of Flag-tagged SENP-1 (0.25–0.75 µg). Samples 
isolated by V5-immunoprecipitation were analyzed by SDS-PAGE and immunoblotting as indicated above. 
Full-length blots are presented in Supplementary Fig. S4. This experiment was replicated in two independent 
experimental days (n = 2).
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cells co-transfected with SUMO-1. Moreover, the presence of PIASγ in the co-transfection further enhanced the 
efficiency of SUMO-3 conjugation of HNF-1A, but seemed not to affect SUMO-1 conjugation. No high molecu-
lar-mass bands could be observed in control samples with HNF-1A alone or in samples transfected with empty 
vector and the SUMOylation machinery. Furthermore, in the input samples (Fig. 1a) we could also observe a clear 
difference in the level of conjugation of SUMO-1 versus SUMO-3 to proteins in general, where the latter seemed 
to be more frequently conjugated to proteins in HEK293 cells. Moreover, the presence of PIASγ further increased 
the level of total SUMO-3 conjugated proteins (Fig. 1a), but seemed to have no effect on SUMO-1 conjugation. 
Next, to further verify that the high molecular-mass bands, seen in the presence of SUMO-3 and PIASγ, indeed 
correspond to HNF-1A SUMOylated forms, we performed an analogous immunoprecipitation experiment in 
the presence of the SUMO-specific protease SENP-1. As shown in Fig. 1b, overexpression by increasing amounts 
of SENP-1 reduced the level of SUMO-3 conjugated HNF-1A bands confirming that HNF-1A is a target for 
SUMO-3 modification. These findings were further supported by our results showing that endogenous mouse 
Hnf-1a from MIN6 cells was modified by exogenous SUMO-3, and the level of SUMO-3 modification increased 
by co-transfection of PIASγ and reduced by the presence of SENP-1 (Supplementary Fig. S1).
K205 and K273 are SUMO-3 target residues in HNF-1A. SUMOylation usually occurs within a spe-
cific SUMO consensus motif described as ψKXE, in which ψ is a large hydrophobic residue, X is any amino acid 
and K (Lysine) is the SUMO conjugation site14. However, SUMOylation at lysine residues outside this motif has 
also been described14,20,21. Using the in silico prediction programs SUMOplot (Abgent) and GPS-SUMO (The 
Cuckoo Workgroup) several lysine residues (K46, K158, K205, K222, K273 and K506) were predicted as pos-
sible candidates for SUMO-conjugation in HNF-1A, with varying scores (Fig. 2a). However, none of the pre-
dicted lysine residues were within a SUMO consensus motif. All predicted lysine mutants were generated and 
their effects on SUMOylation of HNF-1A were examined in HEK293 cells. K205R, K273R and K506R showed 
substantial reduction in the intensity of the higher molecular mass SUMOylated HNF-1A bands compared to 
WT (Fig. 2b,c), indicating that these three residues represent HNF-1A SUMOylation sites and were therefore 
chosen for further investigations. Interestingly, overexpression of SUMO-3 and PIASγ seemed to reduce the 
protein level of unmodified WT HNF-1A and all the mutants, observed in input samples (Fig. 2b), and most 
dramatically for the K506R mutant, whose unmodified band was almost undetectable when overexpressed with 
SUMO-3 and PIASγ. Due to the instability of the K506R mutant in the presence of the SUMOylation machinery, 
it was difficult to conclude whether K506 is a true SUMOylation site. Since both the SUMO-site mutants, K205R 
or K273R, showed some degree of SUMOylation, we investigated the level of SUMO-conjugation of a double 
mutant (K205RK273R) and a triple mutant (K205RK273RK506R) in HEK293 cells (Supplementary Fig. S2). 
Both mutants showed a reduced level of higher molecular mass SUMOylated HNF-1A bands compared to WT 
HNF-1A, but both mutants retained some degree of SUMOylation.
HNF-1A transactivation is repressed by PIASγ in MIN6 cells and requires simultaneous HNF-1A 
SUMOylation at K205 and K273. SUMOylation has been shown to affect the activity of many tran-
scription factors, acting in most cases as a repressor of target gene transactivation22,23. We firstly assessed the 
presence and effect of SUMO-3 and PIASγ overexpression on HNF-1A transactivation of a Firefly luciferase 
reporter gene via its regulation of a rat albumin promoter in transfected MIN6 cells Co-expression of SUMO-3 
and PIASγ, significantly reduced the activity of HNF-1A to around 60%, compared to cells transfected with 
HNF-1A alone (100%) (Fig. 3a). While co-expression of SUMO-3 alone did not affect the transcriptional activity 
of HNF-1A, co-transfection with PIASγ alone demonstrated the strongest inhibitory effect and reduced HNF-1A 
transactivation even more than when overexpressed together with SUMO-3 (~40% and ~60%, respectively, com-
pared to HNF-1A alone of 100%) (Fig. 3a). Next, to investigate whether loss of potential SUMO-target lysine 
residues would obviate the PIASγ-mediated repression, the effect of SUMO-3 and/or PIASγ on the transcrip-
tional activity of single mutants (K205R, K273R and K506R), double mutant (K205RK273R) and triple mutant 
(K205RK273RK506R) was assessed (Fig. 3b). The basal activities of all mutants were per se significantly lower 
compared to WT HNF-1A (Supplementary Fig. S3). Similarly to WT, the activity of the single mutants K205R, 
K273R and K506R was also significantly reduced (around 60–70%) in the presence of both SUMO-3 and PIASγ 
(Fig. 3b), supporting that the transcriptional repression does not require HNF-1A SUMOylation at one sin-
gle lysine residue. By contrast, the transactivation activity of the double and triple mutants, K205RK273R and 
K205RK273K506R, were not reduced by either SUMO-3 and PIASγ, or PIASγ alone, indicating that lack of 
SUMOylation at these sites inhibit repression of HNF-1A transactivation (Fig. 3b).
SUMOylation does not affect the DNA binding ability of HNF-1A. Functional investigations 
indicate that the transcriptional activity of some transcription factors are repressed by SUMOylation, either 
by recruiting repressive co-factors24, by influencing their stability25,26 or by affecting their DNA-binding abil-
ity27. Furthermore, members of the PIAS family such as PIAS1 and PIAS3 have been reported to inhibit the 
DNA-binding activity of their protein targets28,29. We therefore aimed to investigate whether reduction in 
HNF-1A transactivation mediated by the SUMOylation machinery could be attributed to loss of DNA binding 
by HNF-1A. Thus, equal amounts of nuclear fractions isolated from HeLa cells overexpressed with WT HNF-1A, 
and in the presence of SUMO-3 and PIASγ, were incubated with a Cyanine 5 label probe, corresponding to the 
HNF-1 binding site of the rat albumin promoter and analyzed by Electrophoretic mobility shift assay (EMSA). 
Specificity of oligonucleotide binding was also verified by a competition assay using increasing amounts of unla-
beled oligonucleotide (Supplementary Fig. S4). DNA-HNF-1A protein complexes were observed in all samples 
(except for negative control), however, with varying intensities indicating altered DNA-binding affinity (Fig. 4). 
More specifically, the presence of SUMO-3 alone or in combination with PIASγ seemed to only slightly impair 
the DNA binding ability of HNF-1A, indicated by reduced intensity of bands corresponding to the HNF-1A-DNA 
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complexes (Fig. 4a). Upon quantification, these bands were estimated to represent a DNA binding ability of ∼70% 
compared to HNF-1A alone, set to 100% (Fig. 4b). On the contrary, co-expression with PIASγ alone did not 
reduce the DNA binding ability of HNF-1A, demonstrated by similar band intensity as HNF-1A expressed alone, 
and estimated to ∼95% (Fig. 4b).
SUMOylation does not alter the total nuclear level of HNF-1A. Previous studies have linked 
SUMOylation as effector of the nuclear localization of certain transcriptional regulators30, by showing for instance 
that SUMOylation negatively regulates their transcription by controlling their nuclear availability and subnu-
clear localization31,32. Based on this, we next aimed to investigate whether SUMOylation affects the nuclear level 
of HNF-1A. The presence of SUMO-3 and PIASγ did not have any notable effect on the nuclear fraction level 
of HNF-1A, indicating that the total nuclear level of HNF-1A is not affected by the SUMOylation machinery 
(Fig. 5a,b). The level of cytosolic HNF-1A, on the other hand, seemed slightly reduced in the presence of the 
SUMOylation machinery, from our immunoblots (Fig. 5a).
To further evaluate the effect of SUMOylation on the subcellular localization of HNF-1A we used immunoflu-
orescence and confocal microscopy of transiently transfected HEK293 cells. These analyses revealed that HNF-1A 
alone was localized throughout the nucleus, apart from the nucleoli, in line with what was reported previously33. 
The same distribution was observed in the presence of the SUMOylation machinery (Fig. 5c), and confirming the 
findings in Fig. 5a,b. Confirmation of the slightly reduced cytosolic levels of HNF-1A was difficult by immunoflu-
orescence, due to weak cytosolic staining compared to strong nuclear signals (Fig. 5c).
Figure 2. K205 and K273 are SUMOylation sites in HNF-1A. (a) Schematic overview of the HNF-1A 
protein highlighting the lysine residues predicted as SUMOylation sites using the in silico prediction 
programs SUMOplot and GPS-SUMO. The predicted motif for covalent SUMO attachment is displayed 
with the lysine residue underlined in red. (b) Site directed mutagenesis of HNF-1A demonstrated loss of 
SUMOylation upon substitution lysine (K) with arginine (R), at residues K205, K273 and K506 in HEK293 
cells. Cells were transfected with V5-tagged HNF-1A (WT or mutants) together with HA-tagged SUMO-3 
and Flag-tagged PIASγ. Lysates were collected in the presence of NEM and protease inhibitors and subjected 
to immunoprecipitation using anti-V5 antibody. The precipitates were separated by SDS-PAGE and 
immunoblotting using anti-HA and anti-V5 antibodies. Full-length blots are presented in Supplementary 
Fig. S5. This experiment was replicated in three independent experimental days (n = 3). (c) Quantification of 
high molecular SUMOylated bands by densiometric analysis is presented as relative fold change compared to 
WT alone (set to 1). Each bar represents a mean of three independent experiments ± SD (n = 3).
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PIASγ interacts with HNF-1A and reduces the protein level of HNF-1A. Next, we examined 
whether the reduction in HNF-1A activity by PIASγ could be mediated by an interaction between HNF-1A 
and PIASγ. HEK293 cells were firstly overexpressed with HNF-1A and PIASγ and co-immunoprecipitation 
Figure 3. HNF-1A transactivation of a rat albumin promoter is repressed by SUMO-3 and PIASγ. (a,b) 
Transactivation analysis of HNF-1A in MIN6 cells transiently transfected with WT HNF-1A or mutants 
K205R, K273R, K506R, K205RK273R and K205RK273RK506R in the presence/absence of plasmids encoding 
SUMO-3, and/or PIASγ, as indicated in the figure, and together with the reporter plasmids pGL3-RA and 
pRL-SV40. Firefly luciferase activity was normalized to Renilla activity (control reporter) and empty vector was 
used as negative control. Each bar (a,b) represents the mean of nine readings ± SD; three parallel readings were 
conducted on each of three experimental days (n = 3). Measurements are given in fold activity relative to WT. 
*indicates p < 0.05, **indicates p < 0.001. EV = empty vector.
Figure 4. PIASγ does not influence the DNA binding ability of HNF-1A. (a) The DNA-binding ability 
of HNF-1A was assessed in nuclear fractions isolated from HeLa cells transiently transfected with WT 
HNF-1A or empty vector, and co-transfected with SUMO-3 and PIASγ. HNF-1A-DNA binding was 
analyzed by electrophoretic mobility shift assay (EMSA) after HNF-1A incubation with a Cy5 labeled DNA 
oligo (corresponding to HNF-1 binding site in the rat albumin). Bound complexes were separated on a 
6% DNA retardation gel and the fluorescence signal was detected at 670 nm. Full-length gel is presented in 
Supplementary Fig. S6. (b) Quantification of binding by densiometric analysis is presented relative to WT alone 
(set to 100%). Each bar represents a mean of three independent experiments ±SD (n = 3).
www.nature.com/scientificreports/
6SCIeNtIfIC RepoRts |  (2018) 8:12780  | DOI:10.1038/s41598-018-29448-w
experiments were performed (Fig. 6). In the HNF-1A immunoprecipitated samples analyzed by Flag-antibody, 
a PIASγ-specific band at ∼75 kDa was observed, only present in the sample transfected both with WT HNF-1A 
and PIASγ, and not in the control sample representing HNF-1A alone (Fig. 6a), indicating that PIASγ interacts 
Figure 5. SUMOylation is not required for nuclear localization of HNF-1A. (a) Subcellular localization 
of HNF-1A was assessed in HeLa cells transiently transfected with V5-tagged WT HNF-1A together with 
constructs expressing HA-tagged SUMO-3 and/or Flag-tagged PIASγ (as indicated), and analyzed by cellular 
fractionation, SDS-PAGE and immunoblotting. ‘N’ indicates nuclear fractions, whereas ‘C’ indicates cytosolic 
fractions. The purity of the fractions was verified using antibodies against the nuclear- (topoisomerase IIα) and 
the cytosol-specific (GAPDH) marker proteins. Full-length blots are presented in Supplementary Fig. S7. (b) 
The level of HNF-1A in the nuclear fractions was normalized to topoisomerase IIα. The results are presented 
relative to the nuclear level of HNF-1A in cells transfected with HNF-1A alone. Each bar represents a mean 
of three independent experiments ±SD (n = 3). (c) HEK293 cells were transiently transfected with constructs 
expressing V5-tagged WT HNF-1A (in green) alone or in combination with HA-tagged SUMO-3 and/or Flag-
tagged PIASγ. Localization of HNF-1A was visualized by immunofluorescence analysis using anti-V5 antibody 
and confocal microscopy. This experiment was replicated in two independent experimental days (n = 2). Cell 
nuclei were stained with DAPI (blue). Scalebar, 10 µm.
www.nature.com/scientificreports/
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with HNF-1A. We further overexpressed the K205R, K273R and K506R mutants (Fig. 6b) and the triple mutant 
K205RK273RK506R (Supplementary Fig. S5) in the presence or absence of PIASγ and performed a similar 
co-immunoprecipitation experiment. Similarly to WT, all mutants were capable of binding to PIASγ (Fig. 6b and 
Supplementary Fig. S5), demonstrated by a PIASγ specific band in each sample, and indicating that the binding of 
PIASγ to HNF-1A is independent of any of these SUMO-target lysine residues. Interestingly, we also noticed that 
overexpression of PIASγ resulted in slightly reduced intensity of the band representing unmodified HNF-1A band 
(Fig. 6a). This effect of PIASγ on HNF-1A protein level was also observed in our initial immunoprecipitation 
experiments (Fig. 2b). Therefore, to assess whether PIASγ affects the stability of HNF-1A, HNF-1A was overex-
pressed in the presence of increasing amounts of PIASγ plasmid in HEK293 cells. A dose-dependent increase in 
PIASγ plasmid significantly reduced the HNF-1A protein level detected in the supernatant fraction after RIPA 
lysis (Fig. 7a,b). Altogether, these results indicate that PIASγ interacts with HNF-1A either directly or indirectly 
through other unknown modifying factors, and that this leads to a reduction in the total HNF-1A protein level.
To explore whether the PIASγ mediated reduction in cytosolic HNF-1A protein could be explained by 
increased proteasomal degradation of HNF-1A, as shown for other proteins34, HEK293 cells were overexpressed 
with HNF-1A in the presence/absence of the SUMOylation machinery, and subsequently treated with the protea-
somal inhibitor MG132 (Fig. 7c,d). An increase in HNF-1A protein from cleared lysate after MG132 treatment 
and RIPA lysis was detected, confirming that HNF-1A is regulated by the proteasomal degradation system in 
the presence or absence of SUMO-3 and PIASγ, as shown before35. No difference, however, in the total level of 
HNF-1A protein was detected after inhibition of the proteasomal degradation system, indicating that the PIASγ 
mediated reduction of HNF-1A protein level observed in Fig. 7a,b is not executed by the proteasomal system.
PIASγ targets HNF-1A to the nuclear periphery and leads to repression of known HNF-1A reg-
ulated target genes. To further pursue the reason for the reduction in protein level of HNF-1A, in cleared 
RIPA lysates when PIASγ was present, we next investigated the pelleted fraction after RIPA lysis, containing cell 
debris, insoluble proteins and membrane fractions. Interestingly, we noticed a markedly increase in HNF-1A pro-
tein in the pelleted samples when PIASγ was present, relative to that in pellet fractions without PIASγ (Fig. 8a,b). 
Figure 6. PIASγ interacts with HNF-1A. (a) Co-immunoprecipitation analysis of HNF-1A and PIASγ from 
HEK293 cells transiently transfected with V5-tagged HNF-1A or empty vector together with Flag-tagged 
PIASγ. Cells were lysed and subjected to immunoprecipitation using anti-V5 antibody. The precipitates 
(left) and 10 µg input (right) were separated by SDS-PAGE and immunoblotting using anti-Flag and anti-V5 
antibodies. This experiment was replicated in two independent experimental days (n = 2). (b) Mutation 
of K205, K273 and K506 in HNF-1A does not affect the binding of PIASγ to HNF-1A. HEK293 cells were 
transiently transfected with WT HNF1A, K205R, K273R or K506R, together with Flag-tagged PIASγ. Lysates 
were analyzed similarly as described in (a) using anti-V5 antibody immunoprecipitation, SDS-PAGE analysis 
and immunoblotting. Full-length blots are presented in Supplementary Fig. S8. This experiment was replicated 
in two independent experimental days (n = 2).
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These results suggest that PIASγ stimulates a subcellular translocation of HNF-1A to a membrane compartment 
where HNF-1A is not released by regular RIPA lysis.
We further investigated this effect of PIASγ on HNF-1A nuclear distribution by immunofluorescence experi-
ments and confocal microscopy in transiently transfected HEK293 cells. Interestingly, co-expression of HNF-1A 
with PIASγ resulted in a redistribution of HNF-1A to the nuclear periphery, where it was observed to co-localize 
with PIASγ based on overlapping immunofluorescence signals (Fig. 8c). Therefore, this observation indicates 
that PIASγ sequesters HNF-1A to the nuclear periphery. To further explore if the HNF-1A/PIASγ interaction and 
re-localization of HNF-1A to the nuclear membrane would lead to a repression of HNF-1A regulated target genes, 
we performed qPCR of three known HNF-1A targets in MIN6 β-cells, i.e. Ace236, Slc2a23 and Crp37, and compar-
ing mRNA levels in cells overexpressed with either HNF1A alone or HNF1A and PIASγ (Fig. 8d). Interestingly, 
the expression of Ace2 and Slc2a2 was reduced in the presence of PIASγ, while the level of Crp was unchanged.
Discussion
Although mutations in HNF1A is the most prevalent inherited type of diabetes, the precise mechanism of how 
its gene product, HNF-1A is regulated, is largely unknown. Recent reports highlight the importance of balance 
of PTMs in insulin-producing β-cells for maintenance of glucose homeostasis, and in particular the role of 
SUMOylation38,39. In this study, we therefore investigated whether SUMOylation might be a crucial mechanism 
for the normal regulation of HNF-1A.
Different SUMO isoforms serve distinct functional roles by their modification of individual proteins40. For 
instance, while RanGAP1 is predominantly modified by SUMO-1, and to lesser extent by SUMO-341, SUMO-3 
Figure 7. PIASγ reduces the cytosolic HNF-1A protein level in a dose- dependent manner. (a) Effect of 
PIASγ on HNF-1A protein in cleared lysates from transiently transfected HEK293 cells, with V5-tagged 
HNF-1A together with increasing amounts of Flag-tagged PIASγ (0.5–2 µg), and analyzed by SDS-PAGE and 
immunoblotting using indicated antibodies. Full-length blots are presented in Supplementary Fig. S9. (b) The 
level of HNF-1A was normalized to actin and presented relative to the level of HNF-1A alone. The results are 
shown as mean of four independent experiments ±SD (n = 4). *Indicates p < 0.05. (c) HEK293 cells were 
transiently transfected with V5-tagged HNF-1A in the presence or absence of HA-SUMO-3 and Flag-tagged 
PIASγ. Post-transfection, cells were treated with 10 µg MG132 or DMSO for 8 hours, and protein from cleared 
lysates was analyzed by SDS-PAGE and immunoblotting using indicated antibodies. Full-length blots are 
presented in Supplementary Fig. S10. (d) Quantification of proteins shown in c) by densiometric analysis. 
The level of HNF-1A was normalized to the loading control (actin). Each column represents the mean fold 
difference in the MG132-treated samples versus DMSO-treated control on two different experimental days ± 
SD (n = 2).
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Figure 8. PIASγ translocates HNF-1A to the nuclear periphery and leads to reduced expression of known HNF-1A 
target genes. (a,b) After RIPA lysis, pelleted fractions from HEK293 cells transiently transfected with V5-tagged 
HNF-1A in the absence/presence of PIASγ were analyzed by SDS-PAGE and immunoblotting using indicated 
antibodies. The level of HNF-1A was quantified by densiometric analysis using the Image Lab v.6.0.0 software (BIO-
RAD) and normalized to α-tubulin. Full-length blots are presented in Supplementary Fig. S11. Quantifications 
are presented relative to the level of HNF-1A alone. The results are shown as mean of three technical experiments 
(n = 1) ±SD. P indicates parallel. (c) HEK293 cells were transiently transfected with constructs expressing V5-
tagged HNF-1A and/or Flag-PIASγ alone or in combination as indicated in the figure. HNF-1A (green) and 
PIASγ (magenta) were visualized by immunostaining for V5- and Flag-tag, respectively, and analyzed by confocal 
microscopy. Cell nuclei were stained with DAPI (blue). Co-localization of transfected HNF-1A and PIASγ is shown 
in the lower panel. Scalebar, 10 µm. (d) The mRNA expression of three known HNF1A targets genes (Ace2, Slc2a2 
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predominantly modifies nuclear actin42. Our data supports that HNF-1A is preferentially modified by SUMO-3 
compared to SUMO-1 (Fig. 1a). SUMO-3 also seemed to be more frequently conjugated to proteins, in general, 
in the HEK293 cells analyzed, consistent with previous reports showing that SUMO-3 has a substantially higher 
potential to modify cellular proteins than SUMO-141.
Furthermore, the SUMO E3 ligase, PIASγ, increased the level of SUMOylated HNF-1A, which is in line with 
previous findings on the role of PIASγ as a catalyst of SUMOylation43–45.
SUMOylated HNF-1A appeared as multiple high molecular mass bands (Fig. 1). Since SUMO-3 is known to 
be conjugated both alone, or as SUMO chains, at the same target residue46, it is therefore possible that HNF-1A 
is modified by polySUMOylation by SUMO-3 at one target lysine site and/or sequential SUMOylation of mul-
tiple sites. Analyses by both in silico prediction tools and of SUMOylation level assessment of candidate lysine 
mutants identified K205 and K273 as the most important SUMOylation site residues (Fig. 2b,c). The relevance 
of K506 was more difficult to determine, since the K506R mutant was shown to be very unstable in the presence 
and in the absence of the SUMOylation machinery (Fig. 2b, Supplementary Fig. S3 and unpublished data). Thus 
it is possible that the reduction in detectable SUMOylated forms of K506R could be due to a reduction in the 
protein level of K506R, and concealing whether K506 is a true SUMOylation site or not. Since both the dou-
ble mutant (K205RK273R) and triple mutant (K205RK273RK506R) possessed some degree of SUMOylation 
(Supplementary Fig. S2), this suggests that either i) there are more SUMOylation sites in HNF-1A than K205 and 
K273 or ii) there is some redundancy in SUMO-site specificity in HNF-1A, as previously referred to by others on 
different SUMO targets47.
In terms of functional consequence we found that SUMO-3/PIASγ significantly reduced HNF-1A transacti-
vation activity (Fig. 3a). This repression seemed not to be dependent on HNF-1A SUMOylation at single lysines 
K205 and K273, since the transcriptional activity of the SUMOylation–deficient mutants (K205R and K273R) 
were also inhibited by PIASγ/SUMO3. By contrast, for the double/triple mutants K205RK273R(K506R), we did 
not observe any reduction in transactivation of PIASγ/SUMO-3 or by PIASγ alone (Fig. 3b), indicating that 
simultaneous SUMOylation of these lysines are important for the inhibitory effect observed by PIASγ.
A fact supporting the importance of K205, K273, and K506 within the protein structure of HNF-1A is that 
they are highly conserved among different species and they are also conserved in the paralog HNF-1B. Residue 
K205 and K273 are located in the DNA binding domain, while K506 is located in the transactivation domain 
(Fig. 2a). Worth noting is that the baseline transcriptional activity of all the SUMO-site lysine → arginine mutants 
was significantly lower compared to WT HNF-1A activity (Supplementary Fig. S3). One possible explanation 
for their reduced activity might be that these lysines represent important residues for the normal structure and 
activity of HNF-1A. A previous report on K205 shows that this lysine residue is important for inter-domain 
interaction, proper protein folding/structure and stability of HNF-1A, and that loss of this lysine (mutation 
K205Q) leads to reduced protein level due to instability, and hence reduced detectable transcriptional activity48. 
Residue K506 seems also essential for HNF-1A stability and activity as the mutant K506R, in our hands, demon-
strated the lowest level of transcriptional activity of the single mutants (Supplementary Fig. S3), and our immu-
nofluorescence analyses (data not shown) also indicated reduced protein level by weak staining. As mentioned 
earlier, loss of function mutations in HNF1A cause the most common form of monogenic diabetes (HNF-
1A-MODY;MODY3), a disorder characterized by reduced glucose-stimulated insulin secretion5. Interestingly, 
missense variants at K205 (K205Q) and at K273 (K273N) have been associated with MODY348–50. This further 
supports the relevance of these lysine residues for normal HNF-1A function. Accordingly, the normal regulation 
by SUMOylation of these diabetes-associated variants, and SUMOylation site deficient mutants, is most likely 
impaired (Fig. 2b).
Another important aspect of SUMO-conjugation of a target protein is the reversible action by SENPs. 
Interestingly, SENP-1 has recently been shown to be activated by glucose51. Our study confirmed that SENP-1 
successfully de-SUMOylated HNF-1A (Fig. 1b) and Hnf-1a (Supplementary Fig. S1). Given that SUMOylation 
by SUMO-3 has a repressive effect on HNF-1A transcriptional activity, it might be likely that conditions of high 
glucose will activate SENP-1, and subsequent lead to de-SUMOylation of HNF-1A. Ultimately, this may result in 
a more active HNF-1A protein under high glucose.
In our study, the E3 ligase PIASγ revealed to be a new interacting partner of HNF-1A (Fig. 6) and was shown to 
reduce HNF-1A transactivation significantly using a rat albumin promoter in a luciferase assay (Fig. 3a). Further, 
we showed that HNF1A/PIASγ co-transfection reduced the expression of known HNF-1A target genes, i.e. Ace2 
and Slc2a2, in MIN6 cells (Fig. 8d). Previous studies have shown that PIASγ can repress transcription either by 
recruiting transcriptional corepressors52, or by re-localization of the transcription factor within the nucleus45. A 
PIASγ mediated translocation of HNF-1A to the nuclear membranes is supported in our study, and shown by 
immunofluorescence and confocal imaging analyses, as well as analyses of cell pelleted fractions (Fig. 8). PIASγ 
has previously been reported to translocate the CCAAT/enhancer binding protein δ from transcriptionally active 
nuclear foci to the nuclear periphery, and as a result represses the transcriptional ability of protein δ53. According 
to previous studies, the nuclear periphery, and especially the inner nuclear envelope, are cellular areas that have 
been involved in the modulation of gene expression54. More specifically, inner nuclear membrane proteins such 
as lamins and emerins have shown to physically interact with several transcription factors when these enter the 
nucleus. By this, they restrict transcription factor access to their target genes in the nucleosome where tran-
scription occurs, and hence induce transcriptional repression55,56. We believe that the repression by PIASγ on 
and Crp) was investigated in MIN6 cells overexpressed with HNF1A in the absence or presence of PIASy and was 
determined by qPCR. Target gene expression was normalized to reference gene Gapdh and represented as mean fold 
change relative to HNF1A alone ±SD of two biological replicates (n = 2).
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HNF-1A transactivation may be due to PIASγ-mediated sequestration of HNF-1A to the nuclear periphery and 
subsequent restricted access of HNF-1A to its target genes, as demonstrated by reduced mRNA expression for 
Ace2 and Slc2a2 observed in the presence of PIASγ (Fig. 8d). An attractive hypothesis is that this PIASγ-mediated 
repression of HNF-1A activity occurs at low glucose conditions and in β-cell resting state.
In summary, we report here that SUMOylation of HNF-1A represents a novel post translational regulatory 
mechanism of HNF-1A. Further, we have identified PIASγ as a novel HNF-1A interaction partner that enhances 
the SUMOylation of HNF-1A. Furthermore, the PIASγ/HNF-1A interaction leads to re-localization of HNF-1A 
to the nuclear periphery, leading to restricted access to its target genes, thereby reducing the overall HNF-1A 
transcriptional activity. This new knowledge is highly relevant for precision medicine in diabetes as a novel mech-
anism for HNF-1A regulation and altered function by PIASγ, which reveal potential new targets for drug devel-
opment in HNF-1A associated diabetes.
Methods
Cell lines and transfection. MIN6 cells were grown in DMEM (4.5 g/L glucose) supplemented with 
15% heat-inactivated FBS. HEK293 and HeLa cells were grown in DMEM (4.5 g/L glucose) including 10% 
heat-inactivated FBS. All growth media included penicillin/streptomycin. Transfections were performed using 
Lipofectamine-2000 (Invitrogen), if not stated otherwise.
Constructs. HNF1A cDNA (NCBI Entrez Gene BC104910.1) in pcDNA3.1/V5-HisC was used (Life 
Technologies). All HNF1A Lys→Arg variants were constructed using the QuikChange XL Site-directed 
Mutagenesis Kit (Stratagene). Sequences of the primers are shown in Supplementary Table 1. Plasmids encod-
ing human HA-tagged SUMO-1 and SUMO-3 (in pcDNA 3.1) were kindly provided by prof. Frauke Melchior 
(Heidelberg, Germany). Plasmids encoding human HA-tagged UBC9 (p3258 pCMV4) (#14438), Flag-tagged 
PIASγ (pCMV) (#15208) and Flag-tagged SENP1 (pCMV) (#17357) were from Addgene. The Firefly luciferase 
reporter vector pGL3-RA (Promega), containing the promoter of the rat albumin gene (nucleotide −170 to + 5) 
and the pRL-SV40 reporter vector (Promega) encoding the Renilla luciferase gene were used in the transactiva-
tion assay57.
Luciferase assay. MIN6 cells were transiently co-transfected with plasmids expressing WT or variant 
HNF1A cDNA and HA-SUMO3, Flag-PIASγ and reporter plasmids expressing Firefly and Renilla luciferase. Post 
transfection, transactivation was measured using the Dual-Luciferase Assay System (Promega) in a Chameleon 
luminometer (Hidex). Luciferase activity was normalized by Renilla expression.
Co-Immunoprecipitation. HEK293 cells transiently transfected with indicated plasmids and harvested 
using ice-cold IP Lysis/Wash Buffer (Thermo-Fisher) including 20 mM N-ethylmaleimide and protease inhib-
itor cocktail. Protein concentrations were determined in a Direct Detect Spectrometer (Merck Millipore). 
Co-immunoprecipitation (Co-IP) was performed using a V5-antibody (Thermo-Fisher; #R960-25) and the 
Pierce Co-IP kit (Thermo-Fisher). Samples were analyzed by SDS-PAGE and immunoblotting with mouse 
anti-V5 (Thermo-Fisher), rabbit anti-HA (Cell Signaling; #3724), rabbit anti-Flag (Cell Signaling; #2368) and 
horseradish peroxidase (HRP)-linked secondary antibodies.
Endogenously SUMOylated HNF-1A. MIN6 cells, endogenously expressing Hnf-1a, were transiently 
transfected with the indicated plasmids and harvested in ice-cold BlastR lysis buffer supplemented with NEM and 
protease inhibitors (Cytoskeleton). The endogenously SUMOylated Hnf-1a proteins were isolated by immuno-
precipitation using the Signal-Seeker SUMOylation 2/3 Detection Kit (Cytoskeleton), according to the manufac-
turer’s protocol. The eluted samples were analyzed by SDS-PAGE and immunoblotting using rabbit anti-HNF-1A 
(Cell Signaling; # 89670 S), rabbit anti-Flag (Cell Signaling; #2368) and mouse HRP-linked anti-SUMO2/3 
(Cytoskeleton).
Protein expression analysis. HEK293 cells were transiently co-transfected with plasmids expressing 
HNF1A cDNA and increasing amounts of Flag-PIASγ. Post transfection, cells were harvested in RIPA buffer 
(Thermo-Fisher) including 20 mM NEM and protease inhibitor cocktail. Protein concentrations were assessed 
by Pierce™ BCA Protein Assay kit (Thermo-Fisher). Pelleted samples were further treated with Benzonase 
(Sigma-Aldrich) for 30 min 37 °C. Samples were analyzed by SDS-PAGE and immunoblotting using mouse 
anti-V5 (Thermo-Fisher), rabbit anti-Flag (Cell Signaling), goat anti-Actin (Santa Cruz; sc-1615) and anti-alpha 
Tubulin-HRP (Abcam; Ab40742) antibodies.
Electrophoretic mobility shift assay (EMSA). A cyanine 5 labelled oligonucleotide (Sigma Aldrich) 
of PE56 double stranded DNA fragment (5′-TGTGGTTAATGATCTACAGTTA-3′) containing the rat albumin 
sequence (−63/−41) was used. The DNA binding reaction was performed using 10 µg nuclear fractions from 
transiently transfected HeLa cells and the Odyssey EMSA buffer kit (LI-COR Biosciences).
Cell fractionation. HeLa cells transiently transfected with indicated plasmids were harvested in PBS post 
transfection. The cytosolic fraction was collected by re-suspending the cell pellet in buffer A (10 mM Hepes pH 
7.8, 1.5 mM MgCl2, 10 mM KCl, 0.1% IGEPAL, 0.5 mM DTT, EDTA-free protease inhibitor cocktail) followed by 
incubation for 30 min on ice and centrifugation at 17 900 × g for 5 min at 4 °C. Next, the nuclear pellet was washed 
twice with buffer A and further re-suspended in buffer B (20 mM Hepes pH 7.8, 420 mM NaCl, 1.5 mM MgCl2, 
0.2 mM EDTA, 0.5 mM DTT, EDTA-free protease inhibitor cocktail) followed by incubation on ice for 30 min 
vortexing every minute. The nuclear fraction was further collected by centrifugation at 17 900 × g for 15 min 
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4 °C. The protein concentration was determined using the Pierce™ BCA Protein Assay kit (Thermo-Fisher). Each 
fraction was subjected to SDS-PAGE and immunoblotting using rabbit anti-HNF1A (Cell Signaling; #89670) and 
the purity of fractions was verified using antibodies against the nuclear- and cytosol- specific marker proteins 
topoisomerase IIα (Cell Signaling; #12286) and GAPDH (Santa Cruz; sc-47724), respectively.
Immunofluorescence and Confocal microscopy. HEK293 cells were plated on to coverslips and tran-
siently transfected using JetPrime transfection reagent (PolyPlus). Post transfection, cells were fixed using 3% par-
aformaldehyde for 30 min and permeabilized in 1x PBS, 0.1% Tween 20 (PBS-T), 0.1% Triton X-100 for 20 min 
at RT and further incubated in 5% goat serum diluted in PBS-T for 30 min at RT. Cells were then incubated with 
mouse anti-V5 (1:500; Thermo-Fisher) and/or rabbit anti-Flag tag (1:200; Thermo-Fisher; PA1-984B). The sec-
ondary antibodies anti-mouse IgG-Alexa Flour 488 (Thermo-Fisher; A11017) and/or anti-rabbit IgG-Alexa Flour 
594 (Thermo-Fisher; A11037) were used at 1:200. Cells were washed in PBS-T overnight at 4 °C and coverslips 
embedded in ProLong Gold with DAPI (Thermo-Fisher) prior to imaging using TCS SP5 AOBS confocal micro-
scope (Leica Microsystems).
RNA isolation and gene expression analysis by quantitative real-time polymerase chain reac-
tion (qPCR). Total RNA was isolated using the RNeasy mini kit (QIAGEN) from MIN6 cells, transiently trans-
fected with plasmids expressing human HNF1A cDNA and/or human PIASγ. During RNA isolation, an including 
on-column DNase digestion step using the RNase-Free DNase set (QIAGEN) was also included to eliminate 
genomic DNA contamination. cDNA was next synthesized from the total RNA (500 ng) of each sample using the 
SuperScript VILO cDNA Synthesis Kit (Thermo Fisher) and further diluted five times in RNase free water. For 
the qPCR analysis, the TaqMan Universal PCR master mix (Applied Biosystems) and the following TaqMan FAM 
probed (Applied Biosystems) were used: human HNF1A (Hs00167041_m1), human PIASγ (Hs00249203_m1), 
mouse Ace2 (Mm01159003_m1), mouse Crp (Mm00432680_g1), mouse Slc2a2 (Mm00446229_m1) and mouse 
Gapdh (Mm99999915_g1). The amplification reaction was carried out in the ABI Prism 7500 (Thermo-Fisher).
Each reaction was carried out in three replicates and the comparative CT method was used for the relative quan-
tification of the amount of mRNA in each sample normalized to the gapdh transcript levels.
Statistical analysis. All data are presented as mean ± standard deviation (STD) and experiments were 
performed at least on three independent occasions unless otherwise specified. Statistical analysis was performed 
using a two- tailored Student’s t-test and a p value < 0.05 was considered statistically significant.
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